MedPath

Rate of Non-copers to Non-surgical ACL Treatment After 3 Months of Rehabilitation

Recruiting
Conditions
Anterior Cruciate Ligament Injuries
Registration Number
NCT04847258
Lead Sponsor
Vejle Hospital
Brief Summary

The aim is to determine the sensitivity and specificity of a screening tool to identify patients who undergo ACL reconstruction (non-copers) after 3 months of standard rehabilitation following an anterior Cruciate ligament (ACL) injury.

Detailed Description

All included patients are referred to municipal rehabilitation to resolve effusion and range of motion deficits before the first screening (baseline screening) is completed. Hereafter the patients follow 3 months municipal rehabilitation before the second screening (3 months screening). A physiotherapist performs the screening and at the second screening, this is performed prior to consulting an orthopaedic surgeon.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
357
Inclusion Criteria
  • unilateral primary ACL injury
  • Index injury no older than 6 months
Exclusion Criteria
  • Multiligament rupture
  • Large cartillage or meniscus injuries
  • Scheduled ACL reconstruction within 3 months

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Number of patients undergoing ACL reconstruction after 3 months of standard rehabilitation3 months

Patients undergoing ACL reconstruction after 3 months of standard rehabilitation are defined as non-copers to the non-surgical treatment, which will define the sensitivity and specificity of the screening examination.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Vejle Hospital

🇩🇰

Vejle, Region Of Southern Denmark, Denmark

Vejle Hospital
🇩🇰Vejle, Region Of Southern Denmark, Denmark
Kamilla Arp, MSc.
Contact
+4579406796
kamilla.dessau.arp@rsyd.dk
Claus Varnum, ph.d.
Contact
+4579405779
claus.varnum@rsyd.dk

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.